AB 550

This bill prohibits any person from reimbursing certain entities that

participate in the federal drug pricing program, known as the 340B program, for a

drug subject to an agreement under the program at a rate lower than that paid for

the same drug to pharmacies that are similar in prescription volume. The bill also

prohibits a person from imposing any fee, charge back, or other adjustment on the

basis of the entity's participation in the 340B program. The entities covered by the

prohibitions under the bill are federally qualified health centers, critical access

hospitals, and grantees under the federal Ryan White HIV/AIDS program, as well

as these entities' pharmacies and any pharmacy with which any of the entities have

contracted to dispense drugs through the 340B program.